Globus Medical, Inc., a medical device company, focuses on the design, development, and commercialization of musculoskeletal implants that promote healing in patients with spine disorders. The company offers products that address an array of spinal pathologies, anatomies, and surgical approaches. Its fusion products include a range of implant and surgical approach options to treat degenerative, deformity, tumor, and trauma conditions along the spine from the occiput to the sacrum. The company's disruptive technology products comprise products that allow for minimally invasive surgical techniques; and new treatment alternatives, including imaging, navigational, and robotic technologies, as well as motion preservation technologies, such as dynamic stabilization, total disc replacement, and interspinous process spacer products. Its disruptive technology products also consist of regenerative biologics products, including bioactive glass-based bone void fillers and ceramic-collagen for pelvic/extremity and posterolateral spinal fusion procedures; and interventional pain management solutions, which comprise treatments for vertebral compression fractures. In addition, the company offers products for the treatment of orthopedic trauma, including compression screws, fixation plates, intramedullary nails, and external fixation systems. Further, it distributes human cell, tissue, and cellular and tissue based products. The company sells its implants and related disposables primarily to hospitals through direct sales representatives and independent distributors in the United States and internationally. Globus Medical, Inc. was founded in 2003 and is headquartered in Audubon, Pennsylvania.
Industry, Sector and Symbol
Stock Exchange NYSE
Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNYSE:GMED
CUSIP37957720
Phone610-930-1800
Debt
Debt-to-Equity RatioN/A
Current Ratio7.89
Quick Ratio6.46
Price-To-Earnings
Trailing P/E Ratio40.32
Forward P/E Ratio34.08
P/E Growth2.73
Sales & Book Value
Annual Sales$635.98 million
Price / Sales8.16
Cash Flow$1.7791 per share
Price / Cash29.69
Book Value$10.01 per share
Price / Book5.28
Profitability
EPS (Most Recent Fiscal Year)$1.31
Net Income$107.34 million
Net Margins19.91%
Return on Equity15.14%
Return on Assets13.74%
Miscellaneous
Employees1,500
Outstanding Shares98,250,000
Market Cap$5.23 billion
Globus Medical (NYSE:GMED) Frequently Asked Questions
What is Globus Medical's stock symbol?
Globus Medical trades on the New York Stock Exchange (NYSE) under the ticker symbol "GMED."
How were Globus Medical's earnings last quarter?
Globus Medical Inc (NYSE:GMED) announced its quarterly earnings results on Wednesday, August, 1st. The medical device company reported $0.44 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $0.35 by $0.09. The medical device company had revenue of $173.40 million for the quarter, compared to analyst estimates of $168.03 million. Globus Medical had a return on equity of 15.14% and a net margin of 19.91%. The company's quarterly revenue was up 13.8% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.32 EPS. View Globus Medical's Earnings History.
When is Globus Medical's next earnings date?
What guidance has Globus Medical issued on next quarter's earnings?
Globus Medical issued an update on its FY18 earnings guidance on Wednesday, August, 1st. The company provided EPS guidance of $1.55 for the period, compared to the Thomson Reuters consensus estimate of $1.52. The company issued revenue guidance of $700 million, compared to the consensus revenue estimate of $696.16 million.
What price target have analysts set for GMED?
12 analysts have issued 12 month price objectives for Globus Medical's shares. Their predictions range from $36.00 to $65.00. On average, they expect Globus Medical's share price to reach $54.00 in the next year. This suggests a possible upside of 2.2% from the stock's current price. View Analyst Price Targets for Globus Medical.
What is the consensus analysts' recommendation for Globus Medical?
12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Globus Medical in the last year. There are currently 2 sell ratings, 2 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Globus Medical.
Who are some of Globus Medical's key competitors?
Some companies that are related to Globus Medical include ABIOMED (ABMD), ResMed (RMD), DexCom (DXCM), Teleflex (TFX), Hill-Rom (HRC), Insulet (PODD), Haemonetics (HAE), ICU Medical (ICUI), Integra Lifesciences (IART), Penumbra (PEN), Novocure (NVCR), Cantel Medical (CMD), NuVasive (NUVA), Merit Medical Systems (MMSI) and Tandem Diabetes Care (TNDM).
Who are Globus Medical's key executives?
Globus Medical's management team includes the folowing people:
- Mr. David C. Paul, Co-Founder & Exec. Chairman (Age 51)
- Mr. David M. Demski, CEO & Director (Age 60)
- Mr. Anthony L. Williams, Pres & Corp. Sec. (Age 47)
- Mr. David D. Davidar, Co-Founder & Director (Age 52)
- Mr. Daniel T. Scavilla, CFO, Exec. VP & Chief Commercial Officer (Age 53)
Has Globus Medical been receiving favorable news coverage?
News stories about GMED stock have trended somewhat positive on Wednesday, according to Accern Sentiment. The research group rates the sentiment of press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Globus Medical earned a coverage optimism score of 0.18 on Accern's scale. They also assigned headlines about the medical device company an impact score of 46.57 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future. View Recent Headlines for Globus Medical.
Who are Globus Medical's major shareholders?
Globus Medical's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (9.44%), Bank of New York Mellon Corp (1.67%), Bank of New York Mellon Corp (1.66%), Janus Henderson Group PLC (1.44%), Dimensional Fund Advisors LP (1.42%) and Victory Capital Management Inc. (1.37%). Company insiders that own Globus Medical stock include A Brett Murphy, Anthony L Williams, Daniel T Scavilla, David C Paul, David D Davidar, David M Demski, Eric Schwartz and Steven Payne. View Institutional Ownership Trends for Globus Medical.
Which institutional investors are selling Globus Medical stock?
GMED stock was sold by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Point72 Asset Management L.P., Dimensional Fund Advisors LP, Bank of America Corp DE, Van Berkom & Associates Inc., First Light Asset Management LLC, Segall Bryant & Hamill LLC and Oak Ridge Investments LLC. Company insiders that have sold Globus Medical company stock in the last year include A Brett Murphy, Anthony L Williams, Daniel T Scavilla, David C Paul, David D Davidar, David M Demski, Eric Schwartz and Steven Payne. View Insider Buying and Selling for Globus Medical.
Which institutional investors are buying Globus Medical stock?
GMED stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., FMR LLC, Renaissance Technologies LLC, Canada Pension Plan Investment Board, Victory Capital Management Inc., Federated Investors Inc. PA, Capital Fund Management S.A. and Northpointe Capital LLC. View Insider Buying and Selling for Globus Medical.
How do I buy shares of Globus Medical?
Shares of GMED can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Globus Medical's stock price today?
One share of GMED stock can currently be purchased for approximately $52.82.
How big of a company is Globus Medical?
Globus Medical has a market capitalization of $5.23 billion and generates $635.98 million in revenue each year. The medical device company earns $107.34 million in net income (profit) each year or $1.31 on an earnings per share basis. Globus Medical employs 1,500 workers across the globe.
How can I contact Globus Medical?
Globus Medical's mailing address is 2560 GENERAL ARMISTEAD AVENUE, AUDUBON PA, 19403. The medical device company can be reached via phone at 610-930-1800 or via email at [email protected]
MarketBeat Community Rating for Globus Medical (NYSE GMED)
MarketBeat's community ratings are surveys of what our community members think about Globus Medical and other stocks. Vote "Outperform" if you believe GMED will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GMED will underperform the S&P 500 over the long term. You may vote once every thirty days.
